FDA Approves RYZUMVI for Treatment of Presbyopia
The newly approved eye drop offers a non-surgical option for adults dealing with age-related near vision loss.
Updated on Oct. 16, 2026 in Alzheimer’s
Live Poll
Do you believe new medical treatments for common age-related vision changes are a positive development?
The FDA has officially approved RYZUMVI, a phentolamine ophthalmic solution 0.75%, to treat presbyopia in adults. This new eye drop medication works by reducing pupil diameter through a specialized sympatholytic mechanism of action.
Why it matters
Presbyopia affects approximately 90% of adults in the United States over the age of 45, making this a significant development for aging populations. The approval follows positive outcomes from the Phase 3 VEGA-2 and VEGA-3 clinical trials.
RYZUMVI uses a 0.75% concentration of phentolamine, which blocks alpha-1 adrenergic receptors on the iris dilator muscle. During clinical testing, 21% of subjects experienced conjunctival hyperemia and 16% reported instillation site irritation.
The players
FDA
The Food and Drug Administration is the federal agency responsible for regulating food, drugs, and medical devices in the United States.
Viatris Inc.
Viatris is a global healthcare company that manages the exclusive commercialization rights for RYZUMVI in the United States.
Opus Genetics
Opus Genetics is a biotechnology firm that maintains a global licensing agreement for the ophthalmic solution.
The details
The medication functions by reducing pupil diameter without engaging the ciliary muscle, providing a targeted approach to improving near vision. Viatris Inc. holds the exclusive commercialization rights for the product within the United States market.
Timeline
October 16, 2026: The FDA officially approved the phentolamine ophthalmic solution for treating presbyopia.
The Big Picture
The FDA approval follows the specific methodology and successful results generated by the Phase 3 VEGA-2 and VEGA-3 clinical trials. This regulatory milestone marks a successful outcome for the research program that validated the efficacy and safety of the solution.
Patients dealing with presbyopia now have access to a non-invasive, daily eye drop alternative to traditional vision correction methods. Interested individuals should consult their ophthalmologist to discuss if this new medication is appropriate for their specific vision needs.
The takeaway
The introduction of RYZUMVI provides a new pharmaceutical option for the millions of aging adults struggling with near vision loss. Readers should prioritize professional medical advice when considering new eye care treatments to ensure the product is safe for their individual circumstances.
Further reading
For more information on eye health developments, visit the United States Alzheimer’s section.
Live Poll
Do you believe new medical treatments for common age-related vision changes are a positive development?
